Coherus Oncology, Inc. reported LOQTORZI net revenue of $10.0 million for the second quarter of 2025, representing a 36% increase over Q1 2025 and a 163% increase from Q2 2024. Net revenue from continuing operations was approximately $10.3 million for the quarter.
The company reported a net loss from continuing operations of $44.9 million, or $(0.39) per diluted share, for Q2 2025, an improvement from a net loss of $54.9 million, or $(0.48) per diluted share, in Q2 2024. Net income from discontinued operations was $342.6 million, or $2.95 per diluted share, primarily driven by the $339.1 million net gain on the UDENYCA divestiture in April 2025.
As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $237.6 million, with a projected cash runway through 2026, extending beyond key data readouts. During Q2 2025, Coherus used UDENYCA sale proceeds to repay substantially all of its $230 million in 2026 Convertible Notes and buy out UDENYCA royalty rights for $47.7 million. Data readouts for pipeline candidates CHS-114 and casdozokitug remain on track for the first half of 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.